{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:28:35Z","timestamp":1791102515130,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ejca.2012.04.012","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T11:04:57Z","timestamp":1337943897000},"page":"2409-2416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma \u2013 A report from the Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers et leuc\u00e9mies de l\u2019Enfant et de l\u2019adolescent (SFCE)"],"prefix":"10.1016","volume":"48","author":[{"given":"V\u00e9ronique","family":"Minard-Colin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Ichante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Orbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Defachelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Dominique","family":"Tabone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Blouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sirvent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Goma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Oberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.04.012_b0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.2910460220","article-title":"Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules","volume":"46","author":"Binet","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0010","first-page":"9","article-title":"Biochemical effects of Navelbine on tubulin and associated proteins","volume":"16","author":"Fellous","year":"1989","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0015","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/cncr.10600","article-title":"Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma","volume":"94","author":"Casanova","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0020","first-page":"227","article-title":"High response rate of vinorelbine in children and adolescents with refractory or recurrent RMSs","volume":"33","author":"Epelman","year":"1999","journal-title":"Med Ped Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11060-006-9176-3","article-title":"A case of relapsing glioblastoma multiforme responding to vinorelbine","volume":"80","author":"Biassoni","year":"2006","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/1078-0432.CCR-05-1541","article-title":"Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children\u2019s Oncology Group","volume":"12","author":"Johansen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.04.012_b0035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/pbc.22133","article-title":"Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children\u2019s Oncology Group study","volume":"53","author":"Kuttesch","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/1097-0142(19880115)61:2<209::AID-CNCR2820610202>3.0.CO;2-L","article-title":"The Intergroup Rhabdomyosarcoma Study-I. A final report","volume":"61","author":"Maurer","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0045","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/1097-0142(19930301)71:5<1904::AID-CNCR2820710530>3.0.CO;2-X","article-title":"The Intergroup Rhabdomyosarcoma Study-II","volume":"71","author":"Maurer","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0055","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2012.04.012_b0060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0065","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.176.5.2722","article-title":"Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines","volume":"176","author":"Taieb","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2012.04.012_b0070","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood-2009-11-251231","article-title":"Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs","volume":"115","author":"Nakahara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.04.012_b0075","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2012.04.012_b0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/0008-5472.CAN-10-1259","article-title":"Cyclophosphamide induces differentiation of Th17 cells in cancer patients","volume":"71","author":"Viaud","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2012.04.012_b0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2012.04.012_b0090","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.20544","article-title":"Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol","volume":"101","author":"Casanova","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0100","series-title":"Investigator\u2019s hand-book: a manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI","author":"National Cancer Institute","year":"1993"},{"key":"10.1016\/j.ejca.2012.04.012_b0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-2125.2002.01581.x","article-title":"Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials","volume":"53","author":"Nguyen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2012.04.012_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ejca.2012.04.012_b0115","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncr.21629","article-title":"Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma","volume":"106","author":"Bisogno","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-03-0175","article-title":"Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors","volume":"10","author":"Wagner","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.04.012_b0125","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cncr.21779","article-title":"Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children\u2019s Oncology Group","volume":"106","author":"Zwerdling","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.cad.0000217426.82702.74","article-title":"Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin","volume":"17","author":"Wagner-Bohn","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2012.04.012_b0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2010.09.015","article-title":"Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study","volume":"47","author":"Geoerger","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/pbc.22544","article-title":"A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children\u2019s Oncology Group study","volume":"55","author":"Beaty","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ejca.2012.04.012_b0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.2006.06.1960","article-title":"Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children\u2019s Cancer Study Group","volume":"25","author":"Vassal","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0150","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1200\/JCO.2010.29.7390","article-title":"Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"28","author":"Mascarenhas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0155","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpba.2007.01.011","article-title":"A high performance liquid chromatography method for vinorelbine and 4-O-deacetyl vinorelbine: a decade of routine analysis in human blood","volume":"44","author":"Puozzo","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ejca.2012.04.012_b0160","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/01.ccm.0000084806.15352.da","article-title":"Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients","volume":"31","author":"de Wildt","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ejca.2012.04.012_b0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpba.2004.12.001","article-title":"Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products","volume":"38","author":"Bouligand","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ejca.2012.04.012_b0170","first-page":"111","article-title":"Chemical stability of two sterile, parenteral formulations of cyclophosphamide (Endoxan) after reconstitution and dilution in commonly used infusion fluids","volume":"46","author":"Beijnen","year":"1992","journal-title":"J Parenter Sci Technol"},{"key":"10.1016\/j.ejca.2012.04.012_b0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1345\/aph.1M578","article-title":"Stability of cyclophosphamide in extemporaneous oral suspensions","volume":"44","author":"Kennedy","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejca.2012.04.012_b0180","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.04.012_b0185","unstructured":"EMA. Committee for proprietary medicinal products (CPMP): note for Guidance on the investigation of bioavailability and bioequivalence. CPMP\/EWP\/QWP\/1401\/98, 2001."},{"key":"10.1016\/j.ejca.2012.04.012_b0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0021-9673(01)00993-1","article-title":"New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces","volume":"926","author":"Van Heugen","year":"2001","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.ejca.2012.04.012_b0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-004-0794-1","article-title":"Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design","volume":"54","author":"Khayat","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2012.04.012_b0200","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","article-title":"Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors","volume":"12","author":"Marty","year":"2001","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T05:57:38Z","timestamp":1542952658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S095980491200353X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.04.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma \u2013 A report from the Soci\u00e9t\u00e9 Fran\u00e7aise des Cancers et leuc\u00e9mies de l\u2019Enfant et de l\u2019adolescent (SFCE)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2012.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}